Skip to content
2000
Volume 18, Issue 5
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

The field of inhaled antibiotics that target Pseudomonas aeruginosa infections has made substantial contributions to the health, disease management, and life expectancies of individuals with cystic fibrosis (CF) over the last three decades [1-3]. This paper reviews some of the recent clinical developments in the field of inhaled antibiotics for CF and briefly describes formulations and ongoing developments for US and/or European regulatory approvals. Lung delivery technologies, in regards to inhaled antibiotics for CF, are also reviewed

Loading

Article metrics loading...

/content/journals/cpd/10.2174/138161212799315975
2012-02-01
2025-05-09
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/138161212799315975
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test